Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Cadila gains on arm getting USFDA's nod for Minocycline Hydrochloride tablets

24-Nov2017

Cadila gains on arm getting USFDA's nod for Minocycline Hydrochloride tablets

Cadila Healthcare is currently trading at Rs. 446.85, up by 3.35 points or 0.76% from its previous closing of Rs. 443.50 on the BSE.

The scrip opened at Rs. 443.20 and has touched a high and low of Rs. 450.40 and Rs. 442.20 respectively. So far 32508 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 329.95 on 26-Dec-2016.

Last one week high and low of the scrip stood at Rs. 454.60 and Rs. 438.05 respectively. The current market cap of the company is Rs. 45781.77 crore.

The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 17.28% and 7.93% respectively.

Cadila Healthcare's wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received the final approval from the United States Food & Drug Administration (USFDA) to market Minocycline Hydrochloride Extended-Release Tablets in strengths of 45 mg, 80 mg, 90 mg, 105 mg, and 135 mg. Zydus also received the tentative approval for Minocycline Hydrochloride Extended-Release Tablets, 55 mg, 65 mg, and 115 mg.

Minocycline Hydrochloride Extended-Release Tablets are a tetracycline-class drug, indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Related News

View all news

SpiceJet flies high on the bourses

Spicejet is currently trading at Rs. 77.25, up by 0.65 points or 0.85% from its previous closing of Rs. 76.60 on the BSE.The scrip opened at Rs. 76.90 and has touched a high and low of Rs. 78.00 and Rs.......

Linde India gains on reporting 62% rise in Q4 net profit

Linde India is currently trading at Rs. 436.00, up by 3.05 points or 0.70% from its previous closing of Rs. 432.95 on the BSE.The scrip opened at Rs. 440.00 and has touched a high and low of Rs. 443.75......

Tata Motors surges on the bourses

Tata Motors is currently trading at Rs. 165.30, up by 1.80 points or 1.10% from its previous closing of Rs. 163.50 on the BSE.The scrip opened at Rs. 165.00 and has touched a high and low of Rs. 166.50......

Top News

View all news

Tata Motors signs LTS agreement with its employees

Tata Motors has signed a long-term wage settlement (LTS) agreement with its employees. Under the agreement, workmen will get a wage rise of Rs 9,000 per month along with other incentives based on performance.......

Canara Bank invites bids from merchant bankers to manage its $350-500 million MTN issue: Report

Canara Bank has reportedly invited bids from merchant bankers to manage its $350-500 million issue of senior unsecured/tier-II capital bonds under its medium-term note (MTN) programme. The issue size may......

Alembic Pharma gets USFDA's nod for Acetazolamide Extended-Release Capsules

Alembic Pharmaceuticals (Alembic) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500......